论文部分内容阅读
目的观察胰激肽原酶与血管紧张素转换酶抑制剂(ACEI)联合应用和单用ACEI治疗糖尿病肾病患者的疗效比较。方法将糖尿病肾病患者随机分为治疗组和对照组各20例。对照组口服依那普利,联合治疗组在对照组的基础上加用胰激肽原酶治疗,观察4周后,两组患者治疗前后24 h尿蛋白、血尿素、血肌酐变化情况。结果两组24 h尿蛋白在治疗后均明显降低,与对照组相比,联合治疗组效果更显著(P<0.01)。结论胰激肽原酶联合ACEI比单用ACEI更能延缓或逆转慢性肾功能衰竭进展。
Objective To compare the efficacy of pancreatic kallikrein with angiotensin converting enzyme inhibitor (ACEI) and ACEI alone in patients with diabetic nephropathy. Methods Patients with diabetic nephropathy were randomly divided into treatment group and control group, 20 cases each. The patients in the control group received enalapril, and the combined treatment group was treated with pancreatic kininogenase on the basis of the control group. The changes of urinary protein, blood urea and serum creatinine 24 h after treatment were observed after 4 weeks. Results The 24 h urinary protein in both groups decreased significantly after treatment. Compared with the control group, the combination therapy group was more effective (P <0.01). Conclusion Pancreatic kallikrein combined with ACEI can delay or reverse the progression of chronic renal failure more than ACEI alone.